MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF-Reference-Cited by-同舟云学术

MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF

Published:2023-12-22 Issue:24 Volume:8 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Kondo Nobuyuki,Utsumi Takahiro,Shimizu Yuki,Takemoto Ai,Oh-hara Tomoko,Uchibori Ken^ORCID,Subat-Motoshi Sophia,Ninomiya Hironori,Takeuchi Kengo^ORCID,Nishio Makoto^ORCID,Miyazaki Yasunari^ORCID,Katayama Ryohei^ORCID

Funder

MEXT/JSPS

AMED

Chugai Foundation for Innovative Drug Discovery Science

Nippon Foundation

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/173688/files/pdf

Reference85 articles.

1. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019

2. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

3. ALKin Lung Cancer: Past, Present, and Future

4. Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

5. Screening for anaplastic lymphoma kinase ( ALK ) gene rearrangements in non‐small‐cell lung cancer in New Zealand

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer;Cancer Letters;2024-11

2. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14